Choosing first-line therapy for chronic lymphocytic leukemia

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Chronic lymphocytic leukemia (CLL) displays a highly variable clinical course.
• Genomic risk stratification is enhancing traditional staging systems for CLL.
• Treatment response and survival have improved significantly over 30 years.

Purpose of the Study:

• To discuss the evolution of contemporary therapeutic approaches for initial CLL treatment.
• To highlight risk-adapted strategies improving clinical outcomes in CLL.
• To address challenges in treating elderly patients or those with comorbidities.

Main Methods:

• Review of contemporary therapeutic approaches for CLL.
• Analysis of genomic risk stratification in CLL management.
• Evaluation of treatment outcomes based on risk-adapted strategies.

Main Results:

• Monoclonal antibodies combined with chemotherapy demonstrate a survival benefit in CLL.
• Newer therapies mitigate adverse prognosis linked to certain genetic features.
• Specific genetic subgroups in CLL continue to face high risks of progression and mortality.

Conclusions:

• Genomic risk stratification is crucial for understanding CLL heterogeneity.
• Risk-adapted therapeutic strategies are essential for improving CLL patient outcomes.
• Addressing challenges in elderly or comorbid CLL patients is critical for effective management.